BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30543736)

  • 1. [A Case of Nivolumab-Induced Isolated Adrenocorticotropic Hormone Deficiency Presenting Dyspnea].
    Ito K; Uchida T; Manabe Y; Miyazaki Y; Itoh H; Mishina M; Okuno H
    Hinyokika Kiyo; 2018 Oct; 64(10):391-395. PubMed ID: 30543736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma].
    Tomizawa M; Nakai Y; Maesaka F; Owari T; Hara R; Miyake M; Inoue T; Anai S; Tanaka N; Fujimoto K
    Hinyokika Kiyo; 2018 Oct; 64(10):397-401. PubMed ID: 30543737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
    Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
    Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
    Mishima Y; Fukaishi T; Inase N; Isogai S
    Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
    Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
    BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
    De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
    BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma].
    Hattahara K; Yamasaki T; Sawada A; Tanigaki K; Endo S; Teramoto Y; Banno H; Fuchigami Y; Suzuki R; Fujiwara M; Hida T; Yoshino T; Kita Y; Goto T; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
    Hinyokika Kiyo; 2019 May; 65(5):157-161. PubMed ID: 31247693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer.
    Kagoshima H; Hori R; Kojima T; Okanoue Y; Fujimura S; Taguchi A; Shoji K
    Auris Nasus Larynx; 2020 Apr; 47(2):309-313. PubMed ID: 31235078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
    Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
    PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.
    Thibault C; Vano Y; Soulat G; Mirabel M
    Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer.
    Fujiwara R; Inamura K; Yuasa T; Numao N; Yamamoto S; Masuda H; Kawauchi A; Takeuchi K; Yonese J
    Int J Clin Oncol; 2020 Jan; 25(1):151-157. PubMed ID: 31522314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
    Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
    J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Int J Clin Oncol; 2020 Apr; 25(4):705-712. PubMed ID: 31858306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eruptive keratoacanthomas secondary to nivolumab immunotherapy.
    Bednarek R; Marks K; Lin G
    Int J Dermatol; 2018 Mar; 57(3):e28-e29. PubMed ID: 29318617
    [No Abstract]   [Full Text] [Related]  

  • 17. Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.
    Dizman N; Bergerot P; Bergerot C; Lanman RB; Raymond VM; Banks KC; Jones J; Pal SK
    Eur Urol; 2018 Feb; 73(2):308-310. PubMed ID: 28844598
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review.
    Gamulin M; Nham E; Rkman D; Antunac Golubić Z; Likić R
    Croat Med J; 2020 Aug; 61(4):326-332. PubMed ID: 32881430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
    Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
    Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    J Immunother; 2020 Jan; 43(1):38-42. PubMed ID: 31567704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.